Assay for bone alkaline phosphatase

Abstract: A process for the determination of the presence or concentration of bone alkaline phosphatase (BAP) enzyme in a fluid which comprises: (a) contacting a sample of the fluid with a first monoclonal antibody for BAP, wherein the first monoclonal antibody is bound to a solid carrier insoluble in the fluid, in order to form an insoluble complex between the first monoclonal antibody and BAP; (b) separating the fluid sample containing unreacted BAP from the insoluble complex of the first monoclonal antibody and BAP; (c) reacting a measured amount of a second, labeled monoclonal antibody to BAP, which antibody is soluble in the fluid, with the insoluble complex of the first monoclonal antibody and BAP, in order to form an insoluble complex of the first monoclonal antibody, BAP, and second, labeled antibody; (d) separating the solid carrier from unreacted second, labeled antibody; (e) measuring either the amount of second, labeled antibody associated with the solid carrier or the amount of unreacted second, labeled antibody; (f) relating the amount of measured second labeled antibody with the amount of labeled antibody measured for a control sample prepared in accordance with steps (a) thru (e), said control sample being known to be free of BAP, to determine the presence of BAP in said fluid sample, or relating the measured amount of labeled antibody for the fluid sample with the amount of labeled antibody measured for samples containing a known amount of BAP prepared in accordance with steps (a) thru (e) to determine the concentration of BAP in the fluid sample; wherein both monoclonal antibodies used are highly specific for BAP, especially in the presence of LAP.

Description: The invention provides a method for detecting the presence and concentration of bone alkaline phosphatase ("BAP") in human body fluids. Elevated BAP levels in serum is symptomatic for serious disorders such as bone metastasis from carcinomas, such as those of the breast and prostate, and Paget's disease (osteitis deformous). Paget's disease is a serious disease affecting primarily those over the age of 40. The disease is slowly progressive, first involving bone resorption followed by a distorted pattem of new growth in bones such as the pelvis, femur, skull, tibia, vertebrae, clavicle and humerus. The disease exhibits gross symptoms such as bowing of the tibia or femur, enlargement of the skull, shortened stature, and severe aching in the affected bones. Neural effects may include deafness or spinal cord compression accompanied by paresis or paraplegia. Until now, the only reliable diagnosis for Paget's disease has been by x-ray examination. Routine assays for serum BAP are confined to measuring total alkaline phosphatase concentration. Several related forms of alkaline phosphatase exist in the serum, specifically those of the intestinal, placental and the hepatic/renal/skeletal groups. These three broad groups can usually be separated using the time-consuming procedure of electrophoretic assay, but until now assays for distinguishing between the clinically important markers of bone and liver alkaline phosphatases ("LAP") were at best ambiguous and time-consuming. The present invention is directed to a convenient, highly specific sandwich immunoassay method for determining specfically the presence or concentration of BAP, especially when in the presence of LAP. WO-A-85/05690 and Biochem. J., vol. 244, 1987, pages 725-733 disclose methods for the differential determination of isoenzymes of alkaline phosphatase. The present invention is directed to forward, reverse and simultaneous sandwich assays for the presence or concentration of human bone alkaline phosphatase ("BAP"). The assays use monoclonal antibodies that are highly specific for BAP, especially when the BAP is in the presence of human liver alkaline phosphatase ("LAP"). Also provided are monoclonal antibodies that are highly specific for BAP, especially in the presence of LAP. Also provided is a kit for detecting the presence or concentration of BAP, comprising a monoclonal antibody for BAP which is bound or could be bound to a solid support, a labeled monoclonal antibody for BAP, and a signal generating substance, if required, wherein both monoclonal antibodies are highly specific for BAP, especially the presence of LAP. These aspects of the invention are described in more detail below. Figure 1 depicts the simultaneous saturation analysis of monoclonal antibody BA1G 121 using radiolabeled, BAP and crude, unlabeled BAP. Figure 2 depicts the simultaneous analysis of monoclonal antibody BA1G 121 using radiolabeled, purified BAP and crude, unlabeled LAP. Figure 3 is similar to Figure 1 except that the monoclonal antibody analyzed is BA1B 067. Figure 4 is similar to Figure 2 except that the monoclonal antibody being analyzed is BA1B 067. Figure 5 depicts the dose-response curve generated with a sandwich assay employing BA1F 419 as the capture antibody, BA1B 067 as the labeled antibody, and either crude LAP or crude BAP extracts as the analyte. Figure 6 is similar to Figure 5, except that BA1G 017 is the labeled antibody. Figure 7 depicts dose response curves for a sandwich assay analyzing human sera samples with elevated concentrations of either BAP or LAP using BA1F 419 as the capture antibody and BA1B 067 as the labelled antibody. Figure 8 is similar to Figure 7 except that monoclonal antibody BA1G 121 is used as the labeled antibody. Figure 9 is similar to Figure 8 except that monoclonal antibody BA1G 339 is used as the labeled antibody. As noted, the present invention is directed to a sandwich assay highly specific for BAP in the presence of LAP and other human alkaline phosphatase isoenzymes. The concept of a sandwich assay in general is described in David et al ., U.S. Pat. Nos. 4,376,110 and 4,486,530, issued March 8, 1983 and December 4, 1984, respectively. The invention also encompasses monoclonal antibodies highly specific for BAP, especially when in the presence of LAP. In particular, one embodiment of the invention is a "forward" assay process for the determination of the presence of or concentration of BAP in a fluid which comprises: (a) contacting a sample of the fluid with a first monoclonal antibody for BAP, wherein the first monoclonal antibody is bound to a solid carrier insoluble in the fluid in order to form an insoluble complex between the first monoclonal antibody and the BAP; (b) separating the fluid sample containing unreacted BAP from the insoluble complex of the first monoclonal antibody and BAP; (c) reacting a measured amount of a second, labeled monoclonal antibody to BAP, which antibody is soluble in the fluid, with the insoluble complex of the first monoclonal antibody and BAP, in order to form an insoluble complex of the first monoclonal antibody, BAP, and second, labeled antibody; (d) separating the solid carrier from unreacted second, labeled antibody; (e) measuring either the amount of second, labeled antibody associated with the solid carrier or the amount of unreacted second, labeled antibody; (f) relating the amount of second labeled antibody measured with the amount of labeled antibody measured for a control sample prepared in accordance with steps (a) through (e), said control sample known to be free of BAP, to determine the presence of BAP in said fluid sample, or relating the amount of labeled antibody measured in said fluid sample with the amount of labeled antibody measured for samples containing known amounts of BAP prepared in accordance with steps (a) through (e) to determine the concentration of BAP in the fluid sample; wherein both monoclonal antibodies used are less than 20% cross-reactive for LAP in the presence of BAP. Another embodiment of the invention is a "reverse" sandwich assay for BAP for the determination of the presence of or concentration of BAP in a fluid which comprises: (a) contacting a sample of the fluid with a measured amount of the first monoclonal antibody for BAP, wherein the first monoclonal antibody is labeled, in order to form a soluble complex between the first monoclonal antibody and BAP; (b) contacting the sample (which now contains the soluble complex) with a second monoclonal antibody to BAP, which second antibody is bound to a solid carrier insoluble in the fluid, with the soluble complex of the first monoclonal antibody and BAP, in order to form an insoluble complex of the first monoclonal antibody, BAP, and second, labeled antibody; (c) separating the solid carrier from unreacted first, labeled antibody; (d) measuring either the amount of first, labeled antibody associated with the solid carrier or the amount of unreacted first, labeled antibody; (e) relating the amount of first labeled antibody measured with the amount of labeled antibody measured for a control sample prepared in accordance with steps (a) through (d), said control sample being known to be free of BAP, to determine the presence of BAP in said fluid sample, or relating the amount of labeled antibody measured for the fluid sample with the amount of labeled antibody measured for samples containing known amounts of BAP prepared in accordance with steps (a) through (d) to determine the concentration of BAP in the fluid sample; wherein both monoclonal antibodies used are less than 20% cross-reactive for LAP in the presence of BAP. Yet another aspect of the present invention involves a "simultaneous" assay for BAP for the determination of the presence of or concentration of BAP enzyme in a fluid, comprising the steps of: (a) simultaneously contacting a sample of the fluid with a first and second monoclonal antibodies for BAP, wherein the first monoclonal antibody is bound to a solid carrier insoluble in the fluid and the second monoclonal antibody is labeled and provided in a measured amount, in order to form an insoluble complex between the first monoclonal antibody and BAP; (b) separating the solid carrier from the fluid sample unreacted second, labeled antibody; (c) measuring either the amount of second, labeled antibody associated with the solid carrier or the amount of unreacted second, labeled antibody; (d) relating the amount of labeled antibody measured with the amount of labeled antibody measured for a control sample prepared in steps (a) through (c), wherein the control sample is known to be free of BAP, to determine the presence of BAP in said sample fluid, or relating the amount of labeled antibody measured for the fluid sample with the amount of labeled antibody measured for samples containing known amounts of BAP prepared in accordance with steps (a) through (c), to determine the concentration of BAP in the fluid sample; wherein both monoclonal antibodies are less than 20% cross-reactive for LAP in the presence of BAP. In a preferred embodiment of the above forward, reverse or simultaneous assays, the first antibody is the product of a cell line different from that of the second monoclonal antibody. In another preferred embodiment of the forward, reverse or simultaneous assays, the first and second monoclonal antibodies are the product of the same cell line. Further preferred embodiments within the above two preferred embodiments include assays wherein the labeled antibody is labeled with a radioisotope, an enzyme, biotin, avidin, a chromogenic substance, or a fluorogenic substance. A preferred embodiment of the invention entails having the monoclonal antibodies chosen from BA1F 419, BA1G 017, BA1G 121, BA1G 151, or BA1G 339. An especially preferred embodiment is that in which the BA1F 419, BA1G 017, BA1G 121, BA1G 151, or BA1G 339 monoclonal antibody is labeled with a radioactive isotope, especially, 125 I, or when the antibody is labeled with an enzyme other than alkaline phosphatase ( e.g. , beta-galactosidase, horseradish peroxidase, etc.), or when the antibody is labeled with biotin, and wherein the amount of labeled antibody is measured by adding a measured amount of streptavidin-conjugated enzyme label where the enzyme is other than an alkaline phosphatase. Other preferred embodiments include the above forward, reverse or simultaneous assays, in which the unlabeled antibody is bound directly or indirectly to a plastic bead, to a porous membrane, or especially when the unlabeled antibody is bound to microparticles, which microparticles may be bound to a porous membrane. Similarly, preferred embodiments of the above forward, reverse or simultaneous assays, wherein the labeled antibody is labeled with a radioactive isotope, an enzyme, biotin, avidin, chromogenic substance, or a fluorogenic substance, includes those wherein the unlabeled monoclonal antibody is bound directly or indirectly to a porous membrane, and especially so when the unlabeled monoclonal antibody is bound to microparticles, which microparticles are bound to a porous membrane. In the present invention, various terms have specific connotations. Thus, "fluid" means human serum, plasma, whole blood, urine or tumor ascites. "Solid carrier" means those supports commonly used in immunometric assays, and which may be made from natural and/or synthetic material. The support required is insoluble in water and can be rigid or non-rigid. Among such supports are filter paper, filtering devices ( e.g ., glass membranes), plastic beads (such as polystyrene beads), test tubes or (multiple) test wells made from polyethylene, polystyrene, polypropylene, nylon, nitrocellulose, and glass microfibres. Also useful are particulate materials such as agarose, cross-linked dextran and other polysaccharides. It will be understood to one skilled in the art that the capture antibody can bind first to the BAP antigen, then bind to the carrier through, for instance, an anti-mouse IgG antibody, an avidin-biotin system, or the like. Preferred embodiments of the invention have the capture antibody being bound to a porous membrane. "Porous membrane" refers to a flexible or rigid matrix made from any of a variety of filtration or chromatographic materials, including glass fibres and micro-fibres, natural or synthetic materials. Fluids should be able to flow into and pass easily through the membrane. The membrane should preferably also have pores of at least about 0.1 micrometer (µ) and preferably at least about 1.0 micrometer (µ). The porous membrane can be used by itself or as part of a more elaborate device. Such devices may include, for example, the ICON® and like devices described in Valkirs et al ., U.S. Patent Nos. 4,632,901 and 4,727,019, issued December 20, 1986 and February 23, 1988, respectively. Other such devices include the TEST-PAK® device of Abbott Laboratories (North Chicago, Illinois), described in European Patent Application No.0 217 403, published April 8, 1987. Still other devices containing the present porous membrane may include the device of Bauer et al ., U.S. Patent No. 3,811,840, issued May 21, 1974, Cole et al . U.S. Patent No. 4,407,943, issued Oct. 4, 1983, Cole et al ., U.S. Patent No. 4,246,339, issued January 20, 1981. Geigel et al ., U.S. Patent No. 4,517,288, issued May 14, 1985, F.S. Intengan, U.S. Patent No. 4,440,301, issued April 3, 1984, M.E. Jolley, U.S. Patent No. 4,704,255, issued November 3, 1987, Tom et al ., U.S. Patent No. 4,366,241, issued December 28, 1982, or Weng et al ., U.S. Patent No. 4,740,468, issued April 26, 1988. The capture monoclonal antibody can be directly or indirectly bound to the membrane. The direct binding can be covalent or non-covalent using methods well-known in the art (for example, the use of glutaraldehyde and aminosilanes). See , for example, "Immobilized Enzymes", Ichiro Chibata, Halstead Press, New York (1978), Cuatrecasas, J. Biol. Chem. 245:3059 (1970), and March et al ., Anal. Biochem. 60 , p. 149 et seq . (1974). The non-covalent binding takes advantage of the natural adhesion to the natural, and especially the synthetic fibers, by antibodies. Thus, appropriately buffered solutions can be mixed with the membrane then evaporated leaving a coating of the desired antibody on the membrane. The indirect method for applying the antibody to the membrane uses microparticles which are bound to the membrane, or both matrix of the membrane, on the surface of the membrane, or to other particles which are in turn bound to the membrane. The particles can be any shape but preferably spherical. The size of the particles should be such that they do not migrate to any significant degree through the membrane. The size of the particles may vary, but in general they should be slightly larger than the minimum pore size of the membrane and smaller than the maximum pore size, or in the alternative, should be larger than the maximum pore size. (Thus, the particles can be bound with the matrix of the membrane, on the surface of the membrane, or to other particles which then are bound to the membrane) The particles can be made up of a variety of naturally-occurring or synthetic materials. Exemplary of such particles are those made from polyethylene, polyacrylates, polyacrylamide, or naturally occurring materials such as cross-linked polysaccharides like agarose, dextran, cellulose, starch and the like. The primary requirement is that materials do not contribute a signal, usually light absorption, that would cause the zone in which the particles were located to have a different signal than the rest of the membrane. The antibody can be covalently or non-covalently bound to the particle. The binding to the particle uses methods similar to those discussed above for binding the antibody directly to the membrane. The particles are usually applied to the membrane in an area smaller than the surface area of the part of the membrane that it is applied to. Several methods known in the art can be employed. One such method employs various mechanical means (or directly) to apply a suspension, frequently aqueous "latex", to the membrane. The methods and use of microparticles for the instant invention are further discussed in Weng et al ., U.S. Patent No. 4,740,468, issued April 26, 1988 Brown et al ., European Patent Application No. 0 217 403, published April 8, 1987, and A.S. Rubenstein, European Patent Application No. 0 200 381, published November 5, 1986. The separation steps for the various assay formats ( e.g. forward, simultaneous, and reverse) can be performed by methods known in the art. Where indicated, a simple washing with buffer followed by filtration or aspiration is sufficient. After washing, it is sometimes appropriate, as with particulate supports to centrifuge the support, to aspirate the washing liquid, add wash liquid again and aspirate. For membranes and filters, an additional washing with buffer often may be sufficient, preferably drawing the liquid through the membrane or filter by applying a vacuum to the opposite side of the membrane or filter or contacting the opposite side of the filter or membrane with a liquid absorbing member that draws the liquid through, for instance, by capillary action. Moderate temperatures are normally employed for carrying out the assay. Constant temperatures during the period of the measurement are generally required only if the assay is performed without comparison with a control sample. The temperatures for the determination will generally range from about 10°C to about 50°C, more usually from about 15°C to about 45°C. The concentration of BAP which may be assayed generally will vary from about 10 -4 to about 10 -10 M, more usually from about 10 -5 to about 10 -8 M. Considerations such as whether the assay is qualitative, semi-quantitative or quantitative, the particular detection device used and the concentration of BAP will normally determine the concentration of other reagents. The term "labeled antibody" indicates the unique anti-BAP, highly non-cross-reactive monoclonal antibodies of the present invention that are labeled by conventional methods to form all or part of a signal generating system. Thus, the present monoclonal antibodies can be covalently bound to radioisotopes such as tritium, carbon-14, phosphorous-32, iodine-125 and iodine-131 by methods well known in the art. For example, 125 I can be introduced by procedures such as the chloramine-T procedure, enzymatically by a lactoperoxidase procedure or by the prelabeled Bolton-Hunter technique. These techniques, as well as others, are discussed in H. Van Vunakis and J.J. Langone, Editors, Methods in Enzymology , Vol. 70, Part A, 1980. For additional examples of radioactive labels, See also , U.S. Patent No. 3,646,346, issued February 29, 1972, and Edwards et al ., U.S. Patent No. 4,062,733, issued December 13, 1977, respectively. Chromogenic labels are those compounds that absorb light in visible or ultraviolet wavelengths. Such compounds are usually dyestuffs and include quinoline dyes. triarylmethane dyes, phthaleins, insect dyes, azo-dyes. anthraquinoid dyes, cyanine dyes, and phenazoxonium dyes. Fluorogenic compounds include those which emit light in the ultraviolet or visible wavelength subsequent to irradiation by light. The fluorogens can be employed by themselves or with quencher molecules. The primary fluorogens are those of the rhodamine, fluorescein and umbelliferone families. The method of conjugation and use of these and other fluorogens is known to those skilled in the art. See , for example, J.J. Langone, H. Van Vunakis et al ., Methods in Enzymology , Vol. 74, Part C, 1981, especially pages 3 through 105. For a representative listing of other suitable fluorogens, see Tom et al ., U.S. Patent No. 4,366,241, issued Dec. 28, 1982. For further examples, see also U.S. Patent No. 3,996,345. These non-enzymatic signal systems are adequate for the present invention. However, those skilled in the art will recognize that enzyme-catalyzed signal system is, in general, more sensitive than a non-enzymatic system. Thus, for the present invention, catalytic labels are the more sensitive non-radioactive labels. Catalytic labels known in the art include single and dual ("channelled") enzymes such as alkaline phosphatase, horseradish peroxidase, luciferase, β-galactosidase, glucose oxidase, (lysozyme, malate dehydrogenase, glucose&phosphate dehydrogenase,) and the like. Examples of dual ("channeled") catalytic systems include alkaline phosphatase and glucose oxidase using glucose-6-phosphate as the initial substrate. A second example of such a dual catalytic system is illustrated by the oxidation of glucose to hydrogen peroxide by glucose oxidase. The hydrogen peroxide produced would react then with a leuco-dye to produce a signal generator. A further discussion of catalytic systems can be found in Tom et al ., U.S. Patent No. 4,366,241, issued December 28, 1982. Also, see Weng et al ., U.S. Patent No. 4,740,468, issued April 26, 1988. The procedures for coupling enzymes to the antibodies are well known in the art. Reagents used for this procedure may include glutaraldelyde, p-toluene-diisocyanate, various carbodiimide reagents, p-benzoquinone m-periodate, N, N 1 -o-phenylenedimaleimide and the like ( see , for example, J.H. Kennedy et al ., Clin. Chim. Acta 70 , 1 (1976)). In another aspect of the invention, any of the above devices and formats may be provided in a kit in packaged combination with predetermined amounts of reagents for use in assaying BAP. Where an enzyme is the label, the reagents will include an antibody that is highly specific for BAP, as described, and which also will be conjugated to the appropriate enzyme, substrate for the enzyme or precursors therefor, including any additional substrates, enzymes, and cofactors and any reaction product to provide the detectable chromophore or fluorophore. The relative amount of the various reagents may be varied widely, to provide for concentrations in solution of the reagents which substantially optimize the sensitivity and specificity of the assay. The reagents can be provided as dry powders, usually in lyophilized form, and may include excipients, which on dissolution, will provide a reagent solution having the appropriate concentration for performing the assay. Chemiluminescent labels also may be used. See , for example, the labels listed in C.L. Maier, U.S. Patent No. 4,104,029, issued August 1, 1978. The substrates for the catalytic systems include simple chromogens and fluorogens such as para-nitrophenyl phosphate (PNPP), β-D-glucose (plus possibly a suitable redox dye), homovanillic acid, o-dianisidine, bromocresol purple powder, 4-alkyl-umbelliferone, luminol, paradimethylaminolophine, paramethoxylophine, and the like. Depending on the nature of the label and catalytic signal producing system, one would observe the signal, by irradiating with light and observing the level of fluorescence; providing for a catalyst system to produce a dye, fluorescence, or chemiluminescence, where the dye could be observed visually or in a spectrophotometer and the fluorescence could be observed visually or in a fluorometer; or in the case of chemiluminescence or a radioactive label, by employing a radiation counter. Where the appropriate equipment is not available, it normally will be desirable to have a chromophore produced which results in a visible color. Where sophisticated equipment is involved, any of the techniques is applicable. The monoclonal antibodies useful in the present invention are obtained by the process disclosed in Milstein and Kohler and reported in Nature 256 , 495-497, 1975. The details of this process now are well-known and will not be repeated here. Generally, however, the procedure involves injecting a mouse with an immunogen. In the current case, the immunogen used is a source rich in BAP, such as a human osteosarcoma cell. The mouse then is sacrificed and cells taken from its spleen are fused with myeloma cells. The result is a hybrid cell, referred to as a "hybridoma," which is capable of stable culturing in vitro . The population of hybridomas is screened and manipulated so as to isolate individual clones each of which secretes a single antibody species to the antigen. Each individual antibody species obtained in this way is the product of a single B cell from the immune animal and is generated in response to a specific antigenic site recognized on the immunogenic substance. When an immunogenic substance is introduced into a living host, the host's immune system responds by producing antibodies to all the recognizable sites on the substance. This "shotgun" approach to producing antibodies to combat the invader results in the production of antibodies of differing affinities and specificities for the immunogenic substance. Accordingly, after the different hybridoma cell lines are screened to identify those that produce antibody to BAP, the antibodies produced by the individual hybridoma cell lines are preferably screened to identify those having the highest affinity for BAP, stimulating their original production before selection for use in the present invention. Selection based on this criterion is believed to help provide the increased sensitivity in the immunometric assays of the present invention. Techniques using polyclonal antibody of the prior art, at best, have affinities for the antigen which are roughly the average of the affinities of all antibodies produced by the immune system. Preferably, the monoclonal antibody selected for use in the invention will have an affinity compatible with the desired sensitivity and range for the test system under consideration. Preferably the antibody will have an affinity of at least about 10 8 liters/mole and, more preferably, an affinity of at least about 10 9 liters/mole. Specifically, as an initial screen, the hybridomas from the initial fusions are screened using a "one-site" assay. In the assay, microtiter plates are coated with goat anti-mouse IgG. Culture supernatant from the initial hybridomas is added to the microtiter plates, incubated, and then washed to bind the anti-BAP monoclonal antibody indirectly to a solid support. Cross-reactivity of the antibodies is checked by adding a crude detergent extract of BAP (from Saos-2 cell, human osteogenic sarcoma) or a crude butanol extract of LAP (from human liver samples), washing the solid support, then measuring the activity of the bound BAP or LAP by measuring its effect on PNPP substrate (para-nitrophenyl phosphate). Those antibodies that bound at least 2.0 times more BAP than LAP (as measured by either enzyme's activity on PNPP) were grown and expanded. The hybridomas were subsequently given a definitive RIA screen for BAP vs LAP cross-reactivity. The RIA used 125 I-labeled BAP or LAP in a competitive assay format. A sample of hybridoma supernatant and measured amounts of labeled and unlabeled BAP or LAP were combined then incubated with a solid support coupled to sheep anti-mouse IgG. The solid support was washed and was placed in a gamma counter. Varying proportions of labeled or cold BAP or LAP were used to perform a saturation analysis for each antibody. Antibodies that were less than 20% cross-reactive for LAP in the presence of BAP (as determined by the concentration of unlabeled antigen required to inhibit 50% of the binding of the labeled antigen) were selected for use in the two-site (or "sandwich") immunometric assay. Those monoclonal antibodies that are less than about 20% cross-reactive with LAP in the presence of BAP are those referred to as "highly specific for BAP, especially in the presence of LAP". As noted, present invention provides monoclonal antibodies that are highly specific for BAP, especially in the presence of LAP. Preferred embodiments of this aspect of the invention include antibodies BA1F 419, BA1G 017, BA1G 121, BA1G 151, and BA1G 339. The hybridomas that produce antibodies BA1B 067, BA1F 419, BA1G 017, BA1G 121, BA1G 151, and BA1G 339, which are referred to by the designation of the antibody they produce, were deposited with the American Type Culture Collection ("ATCC") (Rockville, Maryland) as follows: Hybridoma Deposit Date Accession Number BA1B 067 January 26, 1989 HB 1 0004 BA1F 419 January 26, 1989 HB 1 0005 BA1G 017 January 26, 1989 HB 1 0002 BA1G 121 January 26, 1989 HB 1 0007 BA1G 151 January 26, 1989 HB 1 0003 BA1G 339 January 26, 1989 HB 1 0006 Saos-2 cells are available from the ATCC under accession number HTB 85. As stated earlier, for the two site assay of the instant invention to selectively detect BAP in the presence of LAP, the capture antibody and the labeled antibody, both, must be highly non-cross-reactive with LAP in the presence of BAP. This requirement is graphically demonstrated by Figures 1 through 9. Figures 1 and 2 show the specificity of antibody BA1G 121 for BAP over LAP. The sequential saturation analyses of these Figures employed labeled BAP antigen followed by addition of cold (crude) BAP antigen (for Figure 1) or LAP antigen (Figure 2). The analyses demonstrated that the 50% inhibition concentration of cold antigen differs greatly for BAP and LAP for BA1G 121, thus the antibody was specific for BAP epitopes and highly non-cross-reactive with LAP epitopes. A similar set of experiments with BA1G 067 (Figures 3 and 4) shows the 50% inhibition level in the competitive RIA saturation analyses for BAP and LAP to be approximately the same. Thus, BA1B 067 does not have the required high specificity for BAP over LAP. Those skilled in the art might have predicted that a sandwich or two site assay using one monoclonal antibody highly specific for BAP and non-cross-reactive with LAP and another monoclonal antibody specific for alkaline phosphatases in general but cross-reactive for BAP and LAP would give a highly specific assay for BAP over LAP. For instance, the highly BAP-specific monoclonal antibody could be the capture antibody bound to the solid support. Thus, the sample containing the BAP analyte (and LAP also) could be incubated and the unbound BAP, LAP and other antigens in the test solution could be removed in a wash step. The (labeled) antibody that was non specific for BAP then could be incubated with the complex-containing solid support, followed by washing and the addition of chromogen, fluorogen or chemuluminescent agent, if necessary. The capture antibody highly specific for BAP should, under normal circumstances, enable the assay to distinguish BAP over LAP. A sandwich assay such as this was performed, using the highly specific BA1F 419 antibody as the capture antibody and the cross-reactive BA1B 067 antibody as the labeled antibody (the saturation analysis data for BA1F 419 is given in Example 1). The results of the assays with crude BAP and crude LAP are shown in Figures 5 and 6. Contrary to expectations, the dose response curves set forth in Figure 5 show no significant difference in the detection of LAP and BAP in in vitro conditions. If the same highly specific capture antibody is used but substituting a highly specific (labeled) antibody BA1G 017 for BA1B 067 the assay responds in a markedly different manner, as graphically set forth in Figure 6. The assay essentially does not respond to a difference in the concentration of LAP, while there is a positive dose response curve for a change in BAP concentration. The slopes of other highly specific antibodies used in conjunction with the capture antibody BA1F 419 are also set forth below in conjunction with Example 4. The requirement for both the capture and the labeled antibody to be highly specific for BAP, especially in the presence of LAP, exists not only in sandwich assays for partially purified human samples but with human patient samples obtained in the normal manner for diagnostic purposes. Figure 7 charts the results of a sandwich assay again employing highly specific monoclonal antibody BA1F 419 as the capture antibody and the cross-reactive monoclonal antibody BA1B 067 as the labeled antibody. Little difference is seen in dose response curves in human sera taken from patients whose sera will have elevated levels of LAP (i.e., patients with various forms of liver disease) and those patients whose sera will have elevated levels of BAP (i.e., patients with Paget's Disease or healthy juvenile ("JUV-1") patients). In contrast, Figures 8 and 9 set forth the results of the sandwich assay using the same highly non-cross-reactive capture antibody (SAl F 419) but this time using two highly BAP-specific antibodies (BA1G 339 and BA1G 121, whose RIA data is presented below in Example 2) as labeled antibodies. The difference in dose response curves for these two assays (as depicted in Figures 8 and 9) over the assay depicted in Figure 7 is dramatic. The dose response curves in Figures 8 and 9 show that the assays described in the graphs have a positive response to increasing concentrations of BAP-containing sera (Paget's disease patients and normal juvenile ( i.e. , "JUV-1", "JUV-2", and "JUV-3" patients) versus the flat response to increasing concentrations of sera containing elevated levels of LAP and normal levels of BAP ( i.e. patients with liver disease). Yet another aspect of the present invention is a kit for detecting the presence or concentration of BAP, comprising a monoclonal antibody for BAP which is bound or can be bound to a solid carrier, a labeled monoclonal antibody, and a signal generating substance if required, wherein both monoclonal antibodies are highly specific for BAP, especially in the presence of LAP. Thus, the antibodies and assay formats discussed above and exemplified below can be supplied as a kit. Once again, the solid carrier can either be bound to the capture antibody at the time the reaction between the capture antibody and the BAP takes place, or the solid carrier can be coated with a substance that binds the capture antibody (e.g. sheep anti-mouse antibody) such that the solid carrier binds to the capture antibody after the antibody binds to the BAP antigen. The kit can additionally contain substrate for the enzyme or the requisite precursors for the substrate, including any additional substrates, enzymes, and cofactors and any reaction partner of the enzymic product required to provide the detectable chromophore or fluorophore. In addition, other additives such as ancillary reagents may be included, for example, stabilizers, buffers, and the like. The relative amounts of the various reagents may vary widely, to provide for concentrations in solution of the reagents which substantially optimize the sensitivity and specificity of the assay. The reagents can be provided as dry powders, usually lyophilized, including excipients, which on dissolution will provide for a reagent solution having the appropriate concentrations for performing the assay. Preferred embodiments of the kit use combinations of the antibodies BA1F 419, BA1G 017, BA1G 121, BA1G 151, or BA1G 339 as either the capture or the labeled antibody, or alternatively where the kit uses one of these antibodies as both the capture and the labeled antibody. Experimental The abbreviations used in the following Procedures and Examples have the same meanings commonly used in the art. Thus, for example, "MEM" stands for modified Eagle's medium, "NP-40" stands for Nonidet P-40, "PBS" stands for phosphate-buffered saline, "PNPP" stands for para-nitrophenylphosphate, "BSA" stands for bovine serum albumin, and the like. The following non-limiting Procedures and Examples are set forth to further illustrate the invention. Procedure 1 Purification of Human Bone Alkaline Phosphatase BAP was extracted from the Saos-2 human osteosarcoma cell line (commercially available from the ATCC under the accession number HTB 85) which was grown in complete MEM supplemented with 8% horse serum and 2% fetal calf serum. The cells were scraped from the culture flask and washed twice in PBS by centrifugation followed by incubation in an extraction buffer containing 1% NP-40 in a 0.1 M Tris-HCl buffer, pH 8.0. The cells were extracted for one hour at 25°C with gentle stirring followed by centrifugation at 10,000g for 15 min to remove the cellular debris. The BAP preparations were purified by running the supernatants through an anti-alkaline phosphatase immunoaffinity column consisting of purified anti-alkaline phosphatase monoclonal antibodies (BA1B 067, an antibody that is specific for both BAP and LAP, and is obtained according to Procedure 3 below) coupled to activated agarose beads (Affigel-10, Bio-Rad Laboratories, Richmond, CA.), according to the package insert. The column was washed with extraction buffer followed by elution with buffer containing 125 mM KCl and 10 mM lysine at pH 11. Fractions were collected and assayed for alkaline phosphatase activity. Each fraction was assayed for alkaline phosphatase activity by combining 50 µl of appropriately diluted sample ( i.e. , anywhere between 2 through 200 times, depending on the concentration of the sample) with 100 µl of PNPP solution (1 PNPP tablet (Sigma) in 3 ml of water) in microtiter plates and measuring the rate of PNPP (substrate) turnover at 405 nm in a Vmax microtiter plate reader (Molecular Devices, Palo Alto, CA) in the kinetic reading mode at 25°C. One unit (U) of activity was defined as the quantity of enzyme that catalyzes the hydrolysis of 1 µmole of substrate per minute under these conditions. One unit of activity was considered to equal approximately one microgram of pure BAP (or LAP). Protein-containing fractions were also analyzed by SDS polyacrylamide gel electrophoresis (10-15% gradient reducing gels, Pharmacia Phast gel system, Pharmacia, Uppsala, Sweden). The electrophoretic analysis indicated a purity for BAP of greater than 95%. After electrophoretic analysis, the protein-containing fractions were incubated with sheep anti-mouse IgG (North Valley Farms, San Diego, CA) coupled to cyanogen bromide-activated Sepharose 4B beads (Pharmacia, Upsala, Sweden) (Sepharose is a registered trade mark) to remove mouse IgG. The yields of BAP from the crude detergent extract were typically approximately 50%. Procedure 2 Purification of Human Liver Alkaline Phosphatase LAP was extracted from human liver samples by suspending the diced, washed samples in an extraction buffer consisting of 30% butanol in a buffer at pH 7.5 containing 2 mM MgCl 2 , 0.025 mM ZnCl 2 , 10 mM Tris-HCl, and homogenizing the mixture with a Polytron homogenizer (Brinkman Instruments, Westbury, NY). The homogenate was incubated at 25°C for 16 hr followed by 8 hr at 4°C with gentle stirring. Centrifugation was performed at 9000g for 30 min (Beckman Instruments, Model J2-21, Palo Alto, CA) and the aqueous phase was separated from the butanol phase and the pellet. The aqueous phase was clarified by centrifuging at 20,000g for 20 min. The LAP preparations were purified and analyzed as in Procedure 1. Electrophoretic analysis, as in Procedure 1, of the protein-containing fractions showed that the LAP thus obtained was greater than 90% pure. After electrophoretic analysis, the protein-containing fractions were incubated with sheep anti-mouse IgG as in Procedure 1. The yields of LAP from the crude butanol extract were typically approximately 33%. Example 1 Production and Isolation of Monoclonal Antibodies BA1F 419, BA1G 017, BA1G 121, BA1G 151, and BA1G 339. Balb/c and A/J mice were immunized with Saos-2 cells which had been extracted with a Triton-X (Triton is a registered trade mark) containing buffer. Mice were immunized using complete Freunds adjuvant for the initial injection followed by incomplete Freunds adjuvant at day 14. Boosts (e.g., BA1B - 1 boost, BA1F 419- 2 boosts, BA1G's - 1 boost) were repeated at 14 day intervals with PBS. Fusion of P3.653 myeloma cells and spleen cells from immunized animals were performed according to Kohler and Milstein (1975), as modified and described in Oi and Herzenberg, Selective Methods in Cellular Immunology, Mishell, B.B., and Shigii, S. M., Eds., W. H. Freeman and Company, San Francisco, Chapter 17, (1980). Serum titer determinations and initial screenings of clones were done by the RIA procedure described below. Hybridomas which were identified to be secreting alkaline phosphatase reactive antibodies were grown in mouse ascites. Alkaline phosphatase-reactive antibodies were partially purified for immunoenzymetric assays by sodium sulfate fractionation ("salt cut") of mouse ascites. The salt cut was performed by determining the amount of ascites fluid collected, and adding dropwise sufficient 25% (w/v) sodium sulfate to the ascites with mixing to give a solution wherein the concentration of salt was 18%. The salt solution is then rotated for two hours at room temperature. The solution is then spun in a JA-20 centrifuge (Beckman Instruments, Palo Alta, Ca.) at 10,000 rpm for twenty minutes. The supernatant is removed and the pellet is resuspended in the 18% salt ascites solution. The solution is stirred or shaken again at room temperature for 10 to 15 minutes, spun again at 10,000 rpm, the supernatant is removed and the pellet is resuspended in a minimum volume of 1X PBS. The buffered solution is dialyzed in PBS at 4°C overnight. A portion (10 µl) of the sample is diluted with 1X PBS (1 ml) and the concentration determined at 280 nm. (Formula: Absorbance at 280 nm divided by 1.4 (constant for mouse IgG) x dilution factor = concentration of salt cut ascites in mg/ml). No further purification is required to use the antibodies in the assay set forth below. Example 2 Competitive Radioimmunoassay for BAP-Specific, non-LAP Cross-reactive Monoclonal Antibodies A. Radiolabelling LAP and BAP The purified BAP and LAP enzymes from Procedures 1 and 2 were labeled with 125 I using Chloramine-T to give a specific activity of approximately 18µCi/µg of protein. B. Radioimmunoassay (RIA) i) Determining Antibody Titer The general procedure for the assay entailed adding hybridoma supernatant sample (25 µl) to microtiter plate wells followed by the addition of 50 µl of I-125 labeled, purified BAP. Sepharose 4B beads (Pharmacia, Uppsala, Sweden) coupled with cyanogen bromide (Cuatrecacas, Methods in Enzymology , J. Biol. Chem. 245:3059 (1970) to sheep anti-mouse IgG were added and the plates were incubated overnight at 25°C with gentle shaking. The Sepharose beads from each plate were washed with 0.1% Tween and PBS and collected with a cell harvester on paper discs and the discs were counted in a gamma counter (Iso-Data, Rolling Meadows, IL). This assay was used to measure the ascites titer for anti-BAP antibodies. The titers for clones BA1F 419, BA1G 017, BA1G 121, BA1G 151, BA1G 339 and BA1B 067 are set forth in Table 1, below. ii) Determining Specificity for BAP in the presence of LAP This RIA procedure was also used for simultaneous saturation analysis of BAP for each of the antibodies. The results of this analysis using radiolabeled BAP displaced by either (unlabeled) BAP or unlabeled LAP are set forth in Table 1 and Figures 1 through 4. In general, varying amounts of crude (unlabeled) LAP or BAP (from Procedures 1 and 2) along with fixed amount of radiolabeled BAP were used to obtain these results. Saturation analysis was performed by first determining the 50% titer point of the antibody sample by the above RIA procedure. Varying amounts of crude BAP or LAP then were added to the appropriate dilution of antibody sample along with a fixed amount of purified 125 I BAP tracer antigen. The rest of the procedure was as described above for the RIA. The results of the competitive assays are set forth below in Table 1 below. Concentration of Cold Antigen for 50% Inhibition Antibody Reactivity Ascites Titer (RIA) Isotype ng BAP ng LAP BA1F 419 Non-cross-reactive 1/6,400 IgG1 16.8 >200 BA1G 017 Non-cross-reactive 1/124,000 IgG2a 5.0 >100 BA1G 121 Non-cross-reactive 1/129,000 IgG2a 6.0 >200 BA1G 151 Non-cross-reactive 1/256,000 IgG2a 8.8 >200 BA1G 339 Non-cross-reactive 1/2,000 IgG2a 15.8 >200 BA1B 067 Cross-reactive 1/256,040 IgG2a 4.0 7 Example 3 "One-site" Immunoenzymetric Enzyme Assay A one-site immunoenzymetric assay for the detection of BAP or LAP was performed by drying sheep anti-mouse IgG (North Valley Farms, San Diego, CA) in 10mM sodium phosphate buffer (pH 7.0) on microtiter plates overnight at 37°C. The plates were rinsed with distilled water followed by a 2 minute wash in a 0.1% Tween-20/PBS solution and then rinsed again with distilled water. Plates were blocked with a PBS solution containing 1% BSA and 0.1% Tween-20, for 30 min at 37°C and washed as before. The plates were incubated with 100 µl of culture supernatant from Example 1 for 2 hr at 37°C, washed as above, and then incubated with crude detergent or butanol extract of either BAP or LAP (from Procedures 1 or 2) for 1 hr at 37°C followed by washing with distilled water. PNPP substrate (1 PNPP tablet (Sigma)) in 3 ml water was added for 30 min and the absorbance was read at 405 nm in a Vmax microtiter plate reader. Example 4 Sandwich Assays Specific for Human BAP Procedure A Biotinylation of Anti-BAP Monoclonal Antibodies Monoclonal antibodies BA1G 017, BA1G 121, BA1G 151, BA1G 339, and BA1B 067 (the latter for comparative purposes) were each biotinylated in the following manner. The antibody (1 mg) was dissolved in 0.2M sodium bicarbonate buffer at pH 8.2 (1 ml). To this solution was added biotin N-hydroxy-succinimide ester (120 mg). The resultant solution was incubated on a rotator at 25°C for 1.5 hours then dialyzed against PBS for 16 hours with two changes of PBS. Procedure B The Sandwich Assay - Microtiter Plate The sandwich assay was performed by drying a PBS solution of the capture antibody (BA1F 419) for the assay in a microtiter plate and washing and blocking as described above in Example 3. A solution (5 µg/ml) of biotin-labeled antibody (either BA1G 017, BA1G 121, BA1G 151, BA1G 339, or for comparison, BA1B 067) was added together with 50 µl of the various dilutions of antigen sample (from either Procedures 1 or 2 above) and the plates were incubated for 4 hours at 25°C. The antibody and antigen dilutions were made in a solution consisting of 5% non-fat dry milk (Alba), 0.01% anti-foam A emulsion (Sigma Chemical Co., St. Louis, Missouri) and 0.001% Thimerosol in PBS. The plates were washed and 50 µl of streptavidin-conjugated horseradish peroxidase (Jackson Laboratories Inc., Avondale, PA) (0.1 µg/ml in 0.1% Tween 20% PBS) was added for 1 hr at 25°C. The plates were washed with distilled water then incubated for 15 min with a solution of o-phenylenediamine substrate (Sigma). The plates were read at 490 nm in a microtiter plate spectrophotometer (Bio-Tek ELISA reader, Bio-Tek Instrument Co., Burlington, VT.) The results of assays using BA1F 419 as the capture antibody and BA1G 017, BA1G 151, BA1G 339, or for comparison, BA1B 067, as the labeled antibody in an in vitro assay are set forth in Table 2 and Figures 5 and 6. BAP Tandem Assay: Slope of the Dose-Response Curves Antibody Reactivity BAP LAP Ratio BAP/LAP Response BA1G 017 Non-cross-reactive 1.09 -0.00633 -- BA1G 151 Non-cross-reactive 2.36 0.01430 165.0 BA1G 339 Non-cross-reactive 1.79 0.00587 305.0 BA1B 067 cross-reactive 36.50 33.10000 1.1 Figures 7, 8, and 9 show the results of assays analyzing human sera expected to be rich in either BAP and LAP. BA1F 419 was used as the capture antibody and antibodies BA1G 339 (Fig. 9) and BA1G 121 (Fig. 8) plus BA1B 067 (for comparison, Fig. 7) were used as the biotin-labeled antibodies. The procedure for assays using human sera followed the procedure used in the in vitro assays except the sera was substituted for the extracted antigen. Procedure C The Sandwich Assay - Bead Format Polystyrene beads (5/16 inch diameter) were prepared by linking the antibody covalently to aminopolystyrene beads using dimethyl suberimidate (DMS). I) Polystyrene beads are nitrated in a 100 ml round bottom flask equipped with a stirbar to which 25.0 ml of concentrated sulfuric acid (H 2 SO 4 ) and 12.5 ml of concentrated nitric acid (HNO 3 ) have been added. The mixture is chilled, using an ice bath, until a temperature of 5-10°C is maintained for a minimum of five minutes. One hundred polystyrene beads are added making sure that all beads are in thorough contact with the acid mixture. The mixture is reacted for about 20 minutes at 5-10°C with gentle stirring. The temperature should not exceed 10°C. The beads are filtered using a Buchner funnel. The beads then are poured into cold (4-8°C) deionized water. A volume of water sufficient to completely immerse the beads is used. The water is drained and the rinse is repeated twice more. The washed beads then are aminated in a 100 ml round bottom flask equipped with a stirbar to which 29.5 ml of concentrated hydrochloric acid (HCl) and 29.5 g of stannous chloride (SnCl 2 ) have been added. The mixture should be maintained at room temperature (20-25°C). The nitrated polystyrene beads are added making sure that all beads are in thorough contact with the acid mixture and the mixture is allowed to react for two hours. After the reduction is complete, the beads are drained using a Buchner funnel. All rinses should employ enough buffer/water to thoroughly immerse the beads. The beads then are rinsed for approximately 1 minute by immersing them in 0.1 M HCl, The beads again are drained and the 0.1 M HCl rinse is repeated. The beads are rinsed for approximately 1 minute by immersing them in deionized water. The beads again are drained and the deionized water rinse is repeated. The beads then are rinsed for approximately 1 minute by immersing them in 0.1 M NaOH. The beads are drained and rinsed twice more using deionized water. The beads should be protected from light and stored in 0.20 M sodium phosphate buffer, pH 7.0, 0.1% Sodium Azide at 2-8°C. II) The functionalized beads were treated in a solution of 0.05M DMS in 0.25M triethanolamine at pH 9.3 for 20 minutes at room temperature with gentle agitation. The beads then were washed in 0.05M sodium phosphate buffer at pH 8.0. The beads were then immersed in a solution of the same sodium phosphate buffer containing the BA1G 151 (any other antibody could be used at this point) antibody (0.05 -0.1 mg/ml) at 2-8°C for 18-24 hours. The beads were washed for 1 hour in 0.1M sodium phosphate buffer that is 1.0M in sodium chloride at pH 6.0 followed by incubation for 15-20 minutes in the same buffer that additionally contains 0.2% Tween 20. The beads were washed for 8-12 minutes in the same buffer but without Tween 20 followed by rinsing in deionized water with agitation for 5 minutes. The beads were blocked with 0.1% BSA (Miles Laboratories, Naperville, IL.) in 0.05M sodium phosphate buffer at pH 7.2 for 3 hours at 53°C with agitation at 20 minute intervals. The beads were drained and rinsed three times with 1.0M sodium chloride solution, 0.1M sodium phosphate buffer at pH 6.0, and then stored for future use at 2-8°C in 0.05M sodium phosphate buffer at pH 7.2 that also contains 0.1% sodium azide. All antibodies used for the bead assay were purified by the HPLC procedure of Procedure 3. The antibody ( e.g. , BA1G 151) was labeled to a specific activity of approximately 7-8 µCi/µg of protein by the Glucose Oxidase Lactoperoxidase (GOLP) Iodination method using Enzymobeads (Bio-Rad, CA) according to the package insert. The antigen for calibration and validation was extracted from Saos-2 cells and LAP was extracted from human liver as described above. The extracted antigen was diluted into a matrix consisting of 10% BSA, 0.1% sodium azide, 0.1% mannitol, 0.001% NP-40, 0.1M sodium phosphate-citrate buffer at pH 7.0. The antigen was diluted based on total alkaline phosphate activity measured as above. Calibration was typically made at 0, 0.1, 0.2, 0.4, and 0.6 Units/ml. The assay, using the above reagents and calibrators, was performed as follows: A) add the sample or calibrator to the assay test tube; B) add a solution (100 µl) of the radiolabeled antibody (diluted to give 200,000 cpm per tube) to the tubes; C) add one bead to the tube; D) incubate the mixture on a shaker at room temperature for 2 hours; E) wash the bead 3 times with Tandem®-R wash reagent (Hybritech Incorporated, San Diego, Ca., a detergent solution containing 0.3% sodium azide as a preservative); and F) detect the signal present on the bead with a gamma counter. The above bead assay constitutes a preferred embodiment of the invention. The most preferred conditions for the bead assay format used BA1G 151 as both the capture ( i.e. bead) and the labeled antibody. Other combinations, such as BA1G 151 as the capture and BA1G 121 as the labeled antibody, and vice versa, and BA1G 121 as both capture and labeled antibody, work well and are preferred bead assay conditions. Other combinations of the BA1F 419, BA1G 017, BA1G 121, BA1G 151, or BA1G 339 successfully detected BAP in the bead assay format and are included within the scope of the present invention. Procedure 3 Production of Cross-Reactive Antibody BA1B 067 Monoclonal Antibody BA1B 067 was produced in the manner described in Examples 1 and 3. The analysis described in Example 2 was not carried out on the antibody because purified samples of BAP and LAP were to be obtained only after BA1B 067 had been produced and purified. In addition to the purification step set forth in Example 1, BA1B 067 was purified further by high pressure liquid chromatography column on a Bio-Rad HPLC instrument equipped with a TSK DEAE anion-exchange column (Bio-Rad Laboratories, Richmond, CA) which was eluted with a linear gradient of 20 mM Tris-HCl, pH 8.5 to 300 mmol sodium chloride, 20 mmol Tris-HCl pH 7.0. This purification was used only for manufacture of affinity columns and for purification of antibody for the bead assays.

Claims: A process for the determination of the presence or concentration of bone alkaline phosphatase (BAP) enzyme in a fluid which comprises: (a) contacting a sample of the fluid with a first monoclonal antibody for BAP, wherein the first monoclonal antibody is bound to a solid carrier insoluble in the fluid, in order to form an insoluble complex between the first monoclonal antibody and BAP; (b) separating the fluid sample containing unreacted BAP from the insoluble complex of the first monoclonal antibody and BAP; (c) reacting a measured amount of a second, labeled monoclonal antibody to BAP, which antibody is soluble in the fluid, with the insoluble complex of the first monoclonal antibody and BAP, in order to form an insoluble complex of the first monoclonal antibody, BAP, and second, labeled antibody; (d) separating the solid carrier from unreacted second, labeled antibody; (e) measuring either the amount of second, labeled antibody associated with the solid carrier or the amount of unreacted second, labeled antibody; (f) relating the amount of measured second labeled antibody with the amount of labeled antibody measured for a control sample prepared in accordance with steps (a) through (e), said control sample being known to be free of BAP, to determine the presence of BAP in said fluid sample, or relating the measured amount of labeled antibody for the fluid sample with the amount of labeled antibody measured for samples containing a known amount of BAP prepared in accordance with steps (a) through (e) to determine the concentration of BAP in the fluid sample; wherein both monoclonal antibodies used are less than 20% cross-reactive with liver alkaline phosphatase (LAP) in the presence of BAP. A process for the determination or the presence of concentration of BAP enzyme in a fluid, which comprises: (a) contacting a sample of the fluid with a measured amount of the first monoclonal antibody for BAP, wherein the first monoclonal antibody is labeled, in order to form a soluble complex between the first monoclonal antibody and the BAP; (b) contacting the soluble complex with a second monoclonal antibody to BAP, said second antibody being bound to a solid carrier insoluble in the fluid, in order to form an insoluble complex of the first labeled monoclonal antibody, BAP, and second antibody; (c) separating the solid carrier from the fluid sample and unreacted first, labeled antibody; (d) measuring either the amount of first, labeled antibody associated with the solid carrier or the amount of unreacted first, labeled antibody; (e) relating the measured amount of first labeled antibody with the amount of labeled antibody measured for a control sample prepared in accordance with steps (a) through (d), said control sample being known to be free of BAP, to determine the presence of BAP in said fluid sample, or relating the measured amount of labeled antibody measured for the fluid sample with the amount of labeled antibody measured for samples containing a known amount of BAP prepared in accordance with steps (a) through (d) to determine the concentration of BAP in a fluid sample; wherein both monoclonal antibodies are less than 20% cross-reactive with LAP in the presence of BAP. A process for the determination or the presence of concentration of BAP enzyme in a fluid comprising the steps: (a) simultaneously contacting a sample of the fluid with a first and second monoclonal antibody for BAP, wherein the first monoclonal antibody is bound to a solid carrier insoluble in the fluid and the second monoclonal antibody is labeled and provided in a measured amount in order to form an insoluble complex between the first monoclonal antibody and the BAP antigen; (b) separating the solid carrier from the fluid sample containing unreacted second, labeled antibody; (c) measuring either the amount of second labeled, antibody associated with the solid carrier or the amount of unreacted second, labeled antibody; (d) relating the measured amount of second labeled antibody with the amount of labeled antibody measured for a control sample prepared in accordance with steps (a) through (c), said control sample being known to be free of BAP, to determine the presence of BAP in said fluid sample, or relating the measured amount of labeled antibody measured for the fluid sample with the amount of labeled antibody for samples containing a known amount of BAP prepared in accordance with steps (a) through (c) to determine the concentration of BAP in the fluid sample; wherein the monoclonal antibodies used are less than 20% cross-reactive with LAP in the presence of BAP. A process according to any one of Claims 1 to 3 in which the first monoclonal antibody is the product of a different cell line than said second antibody. A process according to any one of Claims 1 to 3 in which the first and second monoclonal antibodies are the product of the same cell line. A process according to Claims 4 or 5 wherein the labeled antibody is labeled with a radioactive isotope, an enzyme, biotin, avidin, a fluorogenic substance or a chromogenic substance. A process according to Claim 6, wherein the label is the radioactive isotope 125 I. A process according to Claim 6, wherein the label is an enzyme other than alkaline phosphatase. A process according to Claim 6, wherein the labeled antibody is labeled with biotin, and wherein the amount of labeled antibody is measured by adding a measured amount of streptavidin-conjugated enzyme label wherein the enzyme is other than an alkaline phosphatase. A process as claimed in any one of Claims 1 to 9 in which the monoclonal antibody bound to a solid carrier is bound directly or indirectly to a porous membrane. A process as claimed in Claim 10 in which the bound monoclonal antibody is attached to insoluble microparticles, said microparticles being bound to a porous membrane. A process as claimed in any one of Claims 1 to 11 in which the first or second monoclonal antibody is BA1F 419, BA1G 017, BA1G 121, BA1G 151, or BA1G 339, obtainable from hybridomas having, respectively, the deposit accession number ATCC HB 10005, ATCC HB 10002, ATCC HB 10007, ATCC HB 10003, or ATCC HB 10006. A monoclonal antibody for BAP that is less than 20% cross-reactive with LAP in the presence of BAP. A monoclonal antibody of claim 13 that is BA1F 419, BA1G 017, BA1G 121, BA1G 151, or BA1G 339, obtainable from hybridomas having, respectively, the deposit accession number ATCC HB 10005, ATCC HB 10002, ATCC HB 10007, ATCC HB 10003, or ATCC HB 10006. A hydridoma producing a monoclonal antibody for BAP that is less than 20% cross-reactive with LAP in the presence of BAP. A hybridoma of Claim 15 which is ATCC HB 10007, ATCC HB 10005, ATCC HB 10002, ATCC HB 10003, or ATCC HB 10006. A kit adapted for detecting the presence or concentration of BAP which comprises a monoclonal antibody for BAP that is less than 20% cross-reactive with LAP in the presence of BAP. A kit as defined in Claim 17 in which the antibody is BA1F 419, BA1G 017, BA1G 121, BA1G 151, or BA1G 339, obtainable from hybridomas having, respectively, the deposit accession number ATCC HB 10005, ATCC HB 10002, ATCC HB 10007, ATCC HB 10003, or ATCC HB 10006. A kit as defined in Claim 17 or 18 adapted for performing a simultaneous, reverse or sequential assay for the presence or concentration of BAP.

Inventors: HILL CRAIG STEVENS, WOLFERT ROBERT LEWIS, HILL, CRAIG STEVENS, WOLFERT, ROBERT LEWIS
Applicants: HYBRITECH INC, HYBRITECH INCORPORATED
Application year: 1990
Main classification: G01N33
IPC codes: G01N33, C12P21, C12R1